142 related articles for article (PubMed ID: 34226296)
1. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer.
Wu HC; Lin WL; Lin CL; Lin CY; Chen SW; Chen YX; Chen CH; Lee SW; Chen SH; Tsao CJ; Huang WT; Guo HR
Aging (Albany NY); 2021 Jul; 13(13):17337-17348. PubMed ID: 34226296
[TBL] [Abstract][Full Text] [Related]
2. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
Kilic L; Ordu C; Ekenel M; Yildiz I; Keskin S; Sen F; Gural Z; Asoglu O; Kizir A; Aykan F
Med Oncol; 2013; 30(3):660. PubMed ID: 23877872
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
Ustaalioglu BBO; Bilici A; Tilki M; Surmelioglu A; Erkol B; Figen M; Uyar S
J Cancer Res Ther; 2018 Sep; 14(Supplement):S736-S741. PubMed ID: 30249896
[TBL] [Abstract][Full Text] [Related]
5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
[TBL] [Abstract][Full Text] [Related]
7. Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.
Yu JI; Lim DH; Lee J; Kang WK; Park SH; Park JO; Park YS; Lim HY; Kim ST; Lee SJ; Kim S; Sohn TS; Lee JH; An JY; Choi MG; Bae JM; Kim HS; Ahn S
Radiother Oncol; 2018 Nov; 129(2):306-312. PubMed ID: 30037498
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery.
Yu C; Yu R; Zhu W; Song Y; Li T
J Cancer Res Clin Oncol; 2012 Feb; 138(2):255-9. PubMed ID: 22105898
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer.
Kim SW; Noh OK; Kim JH; Chun M; Oh YT; Kang SY; Lee HW; Park RW; Yoon D
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1161-1167. PubMed ID: 28447209
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
11. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
Wang X; Zhao DB; Yang L; Chi Y; Tang Y; Li N; Wang SL; Song YW; Liu YP; Liu WY; Ren H; Zhang T; Wang JY; Chen XS; Fang H; Wang WH; Li YX; Jin J
Br J Cancer; 2018 Feb; 118(3):338-343. PubMed ID: 29235569
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
[TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
16. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy.
Jácome AA; Wohnrath DR; Scapulatempo Neto C; Fregnani JH; Quinto AL; Oliveira AT; Vazquez VL; Fava G; Martinez EZ; Santos JS
Gastric Cancer; 2013 Apr; 16(2):233-8. PubMed ID: 22740060
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Cai Z; Yin Y; Yin Y; Shen C; Wang J; Yin X; Chen Z; Zhou Y; Zhang B
Gastric Cancer; 2018 Nov; 21(6):1031-1040. PubMed ID: 29728791
[TBL] [Abstract][Full Text] [Related]
20. Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection: A Retrospective Study.
Li Q; Li G; Palmer JD; Zhang Z
Am J Clin Oncol; 2017 Aug; 40(4):375-380. PubMed ID: 25503428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
